The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Increases speed to market for drug developers working on nucleic acid therapeutics
Acquisition expands high-value medical platform
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
Lilly plans to hire approximately more than 1,000 new highly-skilled team members
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
Subscribe To Our Newsletter & Stay Updated
